Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PCI-32765 | Other Identifier | Pharmacyclics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PCI-32765 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PCI-32765 | Drug | 420 mg daily or 840 mg daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) | Number of participants who had experienced at least one treatment emergent AEs. | From first dose to within 30 days of last dose of PCI-32765 |
| Measure | Description | Time Frame |
|---|---|---|
| Food Effect Cohort Assessments | Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. | Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Danelle James, M.D., M.A.S | Pharmacyclics LLC. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | United States | ||
| New York Presbyterian Hosptial Cornell Med Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32209572 | Derived | Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res. 2020 Aug 1;26(15):3918-3927. doi: 10.1158/1078-0432.CCR-19-2856. Epub 2020 Mar 24. | |
| 31196847 |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
There are total 133 subjects enrolled however one subject never received treatment. Therefore, number of subjects "Started" the study is listed as 132 subjects.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | PCI-32765 | PCI-32765: 420 mg daily or 840 mg daily. |
| FG001 | Food Effect Cohort | PCI-32765: 420 mg daily |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | PCI-32765 | PCI-32765: 420 mg daily or 840 mg daily |
| BG001 | Food Effect Cohort | PCI-32765: 420 mg daily |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Treatment Emergent Adverse Events (AEs) | Number of participants who had experienced at least one treatment emergent AEs. | Posted | Number | Participants | From first dose to within 30 days of last dose of PCI-32765 |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | PCI-32765 | PCI-32765: 420 mg daily or 840 mg daily |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Febrile neutropenia | Blood and lymphatic system disorders |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Danelle James | Pharmacyclics | 855-427-8846 | medinfo@pcyc.com |
Not provided
| ID | Term |
|---|---|
| D015451 | Leukemia, Lymphocytic, Chronic, B-Cell |
| D016393 | Lymphoma, B-Cell |
| D007945 | Leukemia, Lymphoid |
| D015448 | Leukemia, B-Cell |
| ID | Term |
|---|---|
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C551803 | ibrutinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Progression Free Survival Rate at 24 Months |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. |
| The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months). |
| Percentage of Participants Achieving Response | Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. | The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months). |
| New York |
| New York |
| 10065 |
| United States |
| The Ohio State University | Columbus | Ohio | 43210 | United States |
| Willamette Valley Cancer Institute and Research Center | Springfield | Oregon | 97477 | United States |
| Sarah Cannon | Nashville | Tennessee | 37203 | United States |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | United States |
| University of Vermont and Fletcher Allen Health Care | Burlington | Vermont | 05405 | United States |
| Northwest Cancer Specialists, P.C. | Vancouver | Washington | 98686 | United States |
| Yakima Valley Memorial | Yakima | Washington | 98902 | United States |
| Derived |
| Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. |
| 29470582 | Derived | O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604. |
| 29437592 | Derived | O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2. |
| 26813675 | Derived | Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26. |
| 26182309 | Derived | Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. |
| 25724156 | Derived | de Jong J, Sukbuntherng J, Skee D, Murphy J, O'Brien S, Byrd JC, James D, Hellemans P, Loury DJ, Jiao J, Chauhan V, Mannaert E. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015 May;75(5):907-16. doi: 10.1007/s00280-015-2708-9. Epub 2015 Feb 28. |
| 25381051 | Derived | Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21. doi: 10.1007/s00280-014-2617-3. Epub 2014 Nov 8. |
| 24332241 | Derived | O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan;15(1):48-58. doi: 10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10. |
| 23886836 | Derived | Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25. |
| 23782158 | Derived | Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. |
| BG002 |
| Total |
Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Participants |
|
|
| Secondary | Food Effect Cohort Assessments | Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. | Note: 16 subjects were participated in food effect cohort. However, the PK parameters for 1 subject under Fasted treatment period cannot be reliably estimated. The data for this subject were excluded from Fed/Fasted comparison. | Posted | Number | 90% Confidence Interval | Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design. |
|
|
|
| Secondary | Progression Free Survival Rate at 24 Months | Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. | Posted | Number | 95% Confidence Interval | Percentage of Participants | The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months). |
|
|
|
| Secondary | Percentage of Participants Achieving Response | Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. | Posted | Number | 95% Confidence Interval | Percentage of Participants | The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months). |
|
|
|
| 61 |
| 116 |
| 116 |
| 116 |
| EG001 | Food Effect | PCI-32765: 420 mg daily | 7 | 16 | 16 | 16 |
| Splenomegaly | Blood and lymphatic system disorders |
|
| Idiopathic thrombocytopenic purpura | Blood and lymphatic system disorders |
|
| Lymphocytosis | Blood and lymphatic system disorders |
|
| Atrial fibrillation | Cardiac disorders |
|
| Angina pectoris | Cardiac disorders |
|
| Supraventricular tachycardia | Cardiac disorders |
|
| Vision blurred | Eye disorders |
|
| Abdominal pain | Gastrointestinal disorders |
|
| Diarrhoea | Gastrointestinal disorders |
|
| Abdominal adhesions | Gastrointestinal disorders |
|
| Enterocolitis haemorrhagic | Gastrointestinal disorders |
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders |
|
| Ileus | Gastrointestinal disorders |
|
| Nausea | Gastrointestinal disorders |
|
| Vomiting | Gastrointestinal disorders |
|
| Asthenia | General disorders |
|
| Pyrexia | General disorders |
|
| Systemic inflammatory response syndrome | General disorders |
|
| Pneumonia | Infections and infestations |
|
| Bacteraemia | Infections and infestations |
|
| Cellulitis | Infections and infestations |
|
| Sinusitis | Infections and infestations |
|
| Sepsis | Infections and infestations |
|
| Clostridial infection | Infections and infestations |
|
| Pneumonia viral | Infections and infestations |
|
| Bacterial sepsis | Infections and infestations |
|
| Bronchitis viral | Infections and infestations |
|
| Chronic sinusitis | Infections and infestations |
|
| Citrobacter infection | Infections and infestations |
|
| Clostridium difficile colitis | Infections and infestations |
|
| Cystitis | Infections and infestations |
|
| Device related infection | Infections and infestations |
|
| Gastroenteritis | Infections and infestations |
|
| Herpes zoster disseminated | Infections and infestations |
|
| Joint abscess | Infections and infestations |
|
| Labyrinthitis | Infections and infestations |
|
| Lobar pneumonia | Infections and infestations |
|
| Mycobacterium avium complex infection | Infections and infestations |
|
| Pneumonia cryptococcal | Infections and infestations |
|
| Pneumonia influenzal | Infections and infestations |
|
| Pneumonia streptococcal | Infections and infestations |
|
| Rhinovirus infection | Infections and infestations |
|
| Staphylococcal bacteraemia | Infections and infestations |
|
| Upper respiratory tract infection | Infections and infestations |
|
| Urinary tract infection | Infections and infestations |
|
| Varicella | Infections and infestations |
|
| Vestibular neuronitis | Infections and infestations |
|
| Viral Infection | Infections and infestations |
|
| Viral upper respiratory tract infection | Infections and infestations |
|
| Subdural haematoma | Injury, poisoning and procedural complications |
|
| Laceration | Injury, poisoning and procedural complications |
|
| Hypercalcaemia | Metabolism and nutrition disorders |
|
| Decreased appetite | Metabolism and nutrition disorders |
|
| Dehydration | Metabolism and nutrition disorders |
|
| Hyperglycaemia | Metabolism and nutrition disorders |
|
| Hyponatraemia | Metabolism and nutrition disorders |
|
| Tumour lysis syndrome | Metabolism and nutrition disorders |
|
| Back pain | Musculoskeletal and connective tissue disorders |
|
| Bone lesion | Musculoskeletal and connective tissue disorders |
|
| Bursitis | Musculoskeletal and connective tissue disorders |
|
| Cervical spinal stenosis | Musculoskeletal and connective tissue disorders |
|
| Richter's syndrome | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Chronic lymphocytic leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Leukostasis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Malignant histiocytosis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Peripheral T-cell lymphoma unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Dizziness | Nervous system disorders |
|
| Cerebrovascular accident | Nervous system disorders |
|
| Headache | Nervous system disorders |
|
| Hypertensive encephalopathy | Nervous system disorders |
|
| Transient ischaemic attack | Nervous system disorders |
|
| Cystitis noninfective | Renal and urinary disorders |
|
| Urinary retention | Renal and urinary disorders |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders |
|
| Pleuritic pain | Respiratory, thoracic and mediastinal disorders |
|
| Rash maculo-papular | Skin and subcutaneous tissue disorders |
|
| Hypertension | Vascular disorders |
|
| Orthostatic hypotension | Vascular disorders |
|
| Syncope | Nervous system disorders |
|
| Neutropenia | Blood and lymphatic system disorders |
|
| Thrombocytopenia | Blood and lymphatic system disorders |
|
| Dry eye | Eye disorders |
|
| Cataract | Eye disorders |
|
| Conjunctivitis | Eye disorders |
|
| Constipation | Gastrointestinal disorders |
|
| Dyspepsia | Gastrointestinal disorders |
|
| Stomatitis | Gastrointestinal disorders |
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders |
|
| Dry mouth | Gastrointestinal disorders |
|
| Aphthous stomatitis | Gastrointestinal disorders |
|
| Fatigue | General disorders |
|
| Oedema peripheral | General disorders |
|
| Chills | General disorders |
|
| Malaise | General disorders |
|
| Pain | General disorders |
|
| Allergy to arthropod bite | Immune system disorders |
|
| Bronchitis | Infections and infestations |
|
| Nasopharyngitis | Infections and infestations |
|
| Fungal infection | Infections and infestations |
|
| Gastroenteritis viral | Infections and infestations |
|
| Oral herpes | Infections and infestations |
|
| Contusion | Injury, poisoning and procedural complications |
|
| Arthropod bite | Injury, poisoning and procedural complications |
|
| Weight decreased | Investigations |
|
| Hypokalaemia | Metabolism and nutrition disorders |
|
| Hyperuricaemia | Metabolism and nutrition disorders |
|
| Hypomagnesaemia | Metabolism and nutrition disorders |
|
| Hyperkalaemia | Metabolism and nutrition disorders |
|
| Arthralgia | Musculoskeletal and connective tissue disorders |
|
| Muscle spasms | Musculoskeletal and connective tissue disorders |
|
| Myalgia | Musculoskeletal and connective tissue disorders |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders |
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders |
|
| Joint swelling | Musculoskeletal and connective tissue disorders |
|
| Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Seborrhoeic keratosis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Peripheral sensory neuropathy | Nervous system disorders |
|
| Anxiety | Psychiatric disorders |
|
| Insomnia | Psychiatric disorders |
|
| Cough | Respiratory, thoracic and mediastinal disorders |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders |
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders |
|
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders |
|
| Productive cough | Respiratory, thoracic and mediastinal disorders |
|
| Sinus congestion | Respiratory, thoracic and mediastinal disorders |
|
| Petechiae | Skin and subcutaneous tissue disorders |
|
| Increased tendency to bruise | Skin and subcutaneous tissue disorders |
|
| Rash pruritic | Skin and subcutaneous tissue disorders |
|
| Pruritus | Skin and subcutaneous tissue disorders |
|
| Ecchymosis | Skin and subcutaneous tissue disorders |
|
| Erythema | Skin and subcutaneous tissue disorders |
|
| Rash | Skin and subcutaneous tissue disorders |
|
| Rash macular | Skin and subcutaneous tissue disorders |
|
| Dermatitis acneiform | Skin and subcutaneous tissue disorders |
|
| Hypotension | Vascular disorders |
|
| Vision Blurred | Eye disorders |
|
| Conjuctival hyperaemia | Eye disorders |
|
| Hydrocele | Congenital, familial and genetic disorders |
|
| Diarrhoea | Gastrointestinal disorders |
|
| Vomiting | Gastrointestinal disorders |
|
| Food poisoning | Gastrointestinal disorders |
|
| Nausea | Gastrointestinal disorders |
|
| Abdominal distension | Gastrointestinal disorders |
|
| Haemorrhoids | Gastrointestinal disorders |
|
| Inguinal hernia | Gastrointestinal disorders |
|
| Mouth haemorrhage | Gastrointestinal disorders |
|
| Oral mucosal blistering | Gastrointestinal disorders |
|
| Early satiety | General disorders |
|
| Injection site haematoma | General disorders |
|
| Hypogammaglobulinaemia | General disorders |
|
| Upper respiratory tract infection | Infections and infestations |
|
| Cellulitis | Infections and infestations |
|
| Folliculitis | Infections and infestations |
|
| Furuncle | Infections and infestations |
|
| Skin infection | Infections and infestations |
|
| Urinary track infection | Infections and infestations |
|
| Laceration | Injury, poisoning and procedural complications |
|
| Excoriation | Injury, poisoning and procedural complications |
|
| Facial bones fracture | Injury, poisoning and procedural complications |
|
| Lip injury | Injury, poisoning and procedural complications |
|
| Scratch | Injury, poisoning and procedural complications |
|
| Blood urea increased | Investigations |
|
| Cardiac murmur | Investigations |
|
| Hyperglycaemia | Metabolism and nutrition disorders |
|
| Decreased appetite | Metabolism and nutrition disorders |
|
| Fluid retention | Metabolism and nutrition disorders |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders |
|
| Back pain | Musculoskeletal and connective tissue disorders |
|
| Exostosis | Musculoskeletal and connective tissue disorders |
|
| Muscular weakness | Musculoskeletal and connective tissue disorders |
|
| Pain in jaw | Musculoskeletal and connective tissue disorders |
|
| Plantar fasciitis | Musculoskeletal and connective tissue disorders |
|
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Headache | Nervous system disorders |
|
| Depression | Psychiatric disorders |
|
| Urinary retention | Renal and urinary disorders |
|
| Obstructive uropathy | Renal and urinary disorders |
|
| Urethral haemorrhage | Renal and urinary disorders |
|
| Erectile dysfunction | Reproductive system and breast disorders |
|
| Scrotal oedema | Reproductive system and breast disorders |
|
| Lung infiltration | Respiratory, thoracic and mediastinal disorders |
|
| Nasal mucosal disorder | Respiratory, thoracic and mediastinal disorders |
|
| Actinic keratosis | Skin and subcutaneous tissue disorders |
|
| Blood blister | Skin and subcutaneous tissue disorders |
|
| Rash papular | Skin and subcutaneous tissue disorders |
|
| Blister | Skin and subcutaneous tissue disorders |
|
| Pityriasis | Skin and subcutaneous tissue disorders |
|
| Pseudoporphyria | Skin and subcutaneous tissue disorders |
|
| Skin lesion | Skin and subcutaneous tissue disorders |
|
| Skin ulcer | Skin and subcutaneous tissue disorders |
|
| Urticaria | Skin and subcutaneous tissue disorders |
|
| Hypertension | Vascular disorders |
|
| Lymphoedema | Vascular disorders |
|
| Orthostatic hypotension | Vascular disorders |
|
| Venous insufficiency | Vascular disorders |
|
Not provided
Not provided
| D006425 |
| Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |